The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: Time to change treatment paradigm?

Cancer

Volumn 118, Issue 22, 2012, Pages 5525-5534

  Thomas, Francis ^a   Rosario, Derek J ^a   Rubin, Naomi ^a   Goepel, John R ^b   Abbod, Maysam F ^c   Catto, James W F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

bladder; immunotherapy; progression; surveillance; urothelial cancer

Indexed keywords

BCG VACCINE;

AGE; AGED; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; CORRELATION ANALYSIS; CYSTECTOMY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REVIEW; TRANSITIONAL CELL CARCINOMA; URINARY TRACT MALFORMATION;

ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84868201013     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27587     Document Type: Review

References (27)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Catto JW, Alcaraz A, Bjartell AS, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011; 59: 671-681.
3. Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009; 69: 8472-8481.
4. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from 7 EORTC trials. Eur Urol. 2006; 49: 466-465; discussion 475-477.
5. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666-675.
6. Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010; 57: 60-70.
7. Hall RR, Parmar MK, Richards AB, Smith PH,. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ. 1994; 308: 257-260.
8. Mariappan P, Zachou A, Grigor KM,. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010; 57: 843-849.
9. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R,. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003; 21: 1315-1330.
10. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA,. The economic consequences of prostate and bladder cancer in the UK. BJU Int. 2005; 95: 59-63.
11. Hollenbeck BK, Ye Z, Dunn RL, Montie JE, Birkmeyer JD,. Provider treatment intensity and outcomes for patients with early stage bladder cancer. J Natl Cancer Inst. 2009; 101: 571-580.
12. Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA,. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol. 2004; 45: 292-296.
13. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S,. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int. 2007; 100: 33-36.
14. Robertson AJ, Beck JS, Burnett RA, et al. Observer variability in histopathological reporting of transitional cell carcinoma and epithelial dysplasia in bladders. J Clin Pathol. 1990; 43: 17-21.
15. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR,. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997; 158: 62-67.
16. Sylvester RJ, van der MA, Lamm DL,. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002; 168: 1964-1970.
17. Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56: 247-256.
18. Bohle A, Balck F, von Weitersheim J, Jocham D,. The quality of life during intravesical bacillus Calmette-Guerin therapy. J Urol. 1996; 155: 1221-1226.
19. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol. 2000; 163: 1124-1129.
20. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV,. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial. Eur Urol. 2003; 44: 429-434.
21. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011; 60: 81-93.
22. Ramani VA, Bromage SJ, Clarke NW,. A contemporary standard for morbidity and outcome after radical cystectomy. BJU Int. 2009; 104: 628-632.
23. Rosario DJ, Becker M, Anderson JB,. The changing pattern of mortality and morbidity from radical cystectomy. BJU Int. 2000; 85: 427-430.
24. Hardt J, Filipas D, Hohenfellner R, Egle UT,. Quality of life in patients with bladder carcinoma after cystectomy: first results of a prospective study. Qual Life Res. 2000; 9: 1-12.
25. Hautmann RE, Volkmer BG, Gust K,. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol. 2009; 27: 347-351.
26. Stein JP, Penson DF,. Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int. 2008; 102: 270-275.
27. Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM,. Optimal management of high-risk T1G3 bladder cancer: a decision analysis [serial online]. PLoS Med. 2007; 4: e284.